Clinical Scenario :
A 12-year-old boy with chronic hepatitis B has been followed for 18 months. His investigations on three separate occasions show:
- HBsAg positive
- HBeAg positive
- HBV DNA 5 × 10⁷ IU/mL
- ALT persistently 4× the upper limit of normal
Transient elastography demonstrates significant liver fibrosis.
What is the most appropriate management?
A. Annual follow-up only
B. Repeat HBV DNA after five years
C. Start antiviral therapy with tenofovir or entecavir
D. Administer hepatitis B immune globulin
E. Start oral acyclovir
Correct answer & Explanation:
Answer: C. Start antiviral therapy with tenofovir or entecavir
Explanation: Treatment of Hepatitis B
This child has immune-active chronic hepatitis B, characterized by:
- Persistent HBsAg positivity, confirming chronic HBV infection.
- HBeAg positivity with high HBV DNA (5 × 10⁷ IU/mL), indicating active viral replication.
- Persistently elevated ALT (4× the upper limit of normal) over 18 months, indicating ongoing hepatocellular injury.
- Significant liver fibrosis on transient elastography, demonstrating progressive liver damage.
The combination of high viral replication, persistent biochemical evidence of hepatitis, and significant fibrosis is an indication for antiviral therapy. When antiviral therapy is indicated, tenofovir or entecavir are preferred high-barrier nucleos(t)ide analogues.
Why the other options are incorrect
A. Annual follow-up only
- Appropriate for children in the immune-tolerant or inactive carrier phase without evidence of ongoing liver injury. This patient has persistent hepatitis and fibrosis requiring treatment.
B. Repeat HBV DNA after five years
- Delaying treatment in a child with active hepatitis and fibrosis increases the risk of progression to cirrhosis and hepatocellular carcinoma.
D. Administer hepatitis B immune globulin
- HBIG is used for post-exposure prophylaxis and for newborns of HBsAg-positive mothers. It has no role in treating established chronic hepatitis B.
E. Start oral acyclovir
- Acyclovir has activity against herpesviruses but is ineffective against hepatitis B virus.
High-yield Pearl
Not every child with chronic hepatitis B requires treatment. Antiviral therapy is recommended for immune-active chronic hepatitis B, defined by persistent elevation of ALT, high HBV DNA levels, and evidence of ongoing liver inflammation or fibrosis. The goal of treatment is to suppress viral replication, reduce hepatic inflammation, prevent progression to cirrhosis and hepatocellular carcinoma, and achieve long-term viral suppression.
References
- World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024. WHO guideline
- American Association for the Study of Liver Diseases. Pediatric hepatitis B. Liver Fellow Network.
You can also practice another MCQ on Treatment of Hepatitis C .
